Full history for every metric is available with a Kvantra account
Key financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | €m | 2,336 | 3,449 | 4,175 | 3,396 | 3,381 | 3,538 | 3,582 | 3,713 |
| Operating profit | €m | 651 | 633 | ||||||
| Net profit | €m | 321 | 427 | 913 | 205 | 84 | 155 | 171 | 368 |
| EPS reported | € | 2.24 | 2.83 | ||||||
| Operating cashflow per share | € | 9.50 | 10.64 | ||||||
| Capex per share | € | 6.40 | 6.39 | ||||||
| FCF per share | € | 3.10 | 4.24 | ||||||
| Free cash flow | €m | 214 | 293 | ||||||
| Net debt | €m | 3,524 | 3,547 | ||||||
| Book value equity | €m | 2,707 | 2,823 | ||||||
| Book value per share | € | 39.20 | 40.88 | ||||||
| Number of shares | m | 69.05 | 69.05 | ||||||
| DPS (TTM paid) | € | 0.74 | 0.74 |
Financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 110.36 | 89.40 | ||||||
| P/B LTM | x | 6.31 | 6.15 | ||||||
| P/S LTM | x | 4.82 | 4.85 | ||||||
| P/FCF LTM | x | 79.72 | 59.27 | ||||||
| EV/EBITDA LTM | x | 19.42 | 20.03 | ||||||
| EV/Sales LTM | x | 5.88 | 5.84 | ||||||
| Earnings Yield LTM | % | 0.91% | 1.12% | ||||||
| FCF Yield | % | 1.25% | 1.69% | ||||||
| Quality | |||||||||
| ROE | % | 5.72% | 6.28% | ||||||
| ROIC | % | 5.13% | 5.11% | ||||||
| Operating margin | % | 18.41% | 17.68% | ||||||
| Gross margin | % | 46.26% | 45.71% | ||||||
| FCF/Sales | % | 6.05% | 8.18% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +83.61% | +87.42% | ||||||
| Sales Growth YoY | % | +4.66% | +3.29% | ||||||
| Net Income Growth YoY | % | +84.40% | +28.20% | ||||||
| FCF Growth | % | -62.19% | -49.09% | ||||||
| Operating Profit Growth | % | +48.99% | +26.94% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.30% | 0.29% | ||||||
| Dividend Growth | % | 0.00% | 0.00% | ||||||
| Payout Ratio | % | 32.78% | 26.00% | ||||||
| FCF/Debt | x | 0.05 | 0.07 | ||||||
| Net Debt/EBITDA | x | 3.49 | 3.60 | ||||||
| EBIT/Net interest | x | 3.29 | 2.74 | ||||||
| Net debt/market cap | % | 20.64% | 20.43% | ||||||
| Net debt/Equity | x | 1.30 | 1.26 | ||||||
| Gross debt/equity | x | 1.58 | 1.44 | ||||||
ETFs that hold Sartorius
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| Deka MDAX UCITS ETF | ELF1.DE | 5 | 4.30% |
Funds with Sartorius among their ten largest holdings, largest fund first.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Sartorius AG is a global supplier of advanced bioprocess and laboratory solutions, offering a comprehensive portfolio of products and services essential for life science research and biopharmaceutical manufacturing. The company's offerings include sophisticated biosensors and detection systems, live-cell analysis platforms, and a wide array of cell culture media and reagents. Sartorius also manufactures various bioreactors, ranging from benchtop to large-scale single-use and stainless steel systems, along with their associated software applications. Its extensive filtration product line encompasses membranes, specialized filters, and diverse devices for ultrafiltration, sterile filtration, and sample preparation. Furthermore, Sartorius provides process chromatography and fluid management solutions, industrial microbiology systems, water purification units, and essential lab equipment such as weighing, pipetting, and centrifugation systems. Beyond products, the company delivers critical services including bioprocess development, protein expression, and validation. Serving sectors like life science research, biopharmaceutical manufacturing, and quality control, Sartorius was established in 1870 and is headquartered in Göttingen, Germany.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| Deka MDAX UCITS ETF | ELF1.DE | 5 | 4.30% |
Funds with Sartorius among their ten largest holdings, largest fund first.
Based on consensus from external analysts. Not Kvantra's opinion.
Sartorius AG is a global supplier of advanced bioprocess and laboratory solutions, offering a comprehensive portfolio of products and services essential for life science research and biopharmaceutical manufacturing. The company's offerings include sophisticated biosensors and detection systems, live-cell analysis platforms, and a wide array of cell culture media and reagents. Sartorius also manufactures various bioreactors, ranging from benchtop to large-scale single-use and stainless steel systems, along with their associated software applications. Its extensive filtration product line encompasses membranes, specialized filters, and diverse devices for ultrafiltration, sterile filtration, and sample preparation. Furthermore, Sartorius provides process chromatography and fluid management solutions, industrial microbiology systems, water purification units, and essential lab equipment such as weighing, pipetting, and centrifugation systems. Beyond products, the company delivers critical services including bioprocess development, protein expression, and validation. Serving sectors like life science research, biopharmaceutical manufacturing, and quality control, Sartorius was established in 1870 and is headquartered in Göttingen, Germany.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free